Prediction of response to ergocryptine in the galactorrhea-amenorrhea syndrome.
Forty women with secondary amenorrhea and galactorrhea, thirty-six of whom had associated hyperprolactinemia, were studied prior to therapy with ergocryptine. Abnormal sella tomographic findings were present in 23. The findings on sellar tomography, basal serum prolactin concentrations, and pharmacologic stimulation/suppression of the serum prolactin failed to predict subsequent responders and nonresponders to ergocryptine. Pituitary stimulation for hormone responsiveness did differentiate subsequent responders to ergocryptine from nonresponders. The serum growth hormone response to hypoglycemia was the most definitive predictor. Return of apparently ovulatory function occurred in 29 patients, 11 of whom conceived and have delivered healthy infants.
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005687:Galactorrhea / Q000188:drug therapy*; D006801:Humans; D007775:Lactation Disorders / Q000188:drug therapy*; D010901:Pituitary Function Tests; D011247:Pregnancy; D011379:Prognosis; D011388:Prolactin / Q000097:blood*; D012658:Sella Turcica / Q000033:anatomy & histology
D004873:Ergolines; D011388:Prolactin